Company Overview and News
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 9/14/18. Yields above 12.2% narrowed the list to 30.
AMID AIC MMLP NAP PER HCLP CCLP AI GMLP MDLY AIW USDP SNMP
WallStars are distinguished by positive broker target price upsides. Five top net-gain financial WallStars, MDLY, BLX, GARS, CPTA, and BBVA averaged 42.29% estimated net gains per one-year targets as of September 7, 2018.
AIY CMFN TCRX AINV GARS CLA FSIC AIC GECC TCPC BVA AIB TCRD TCRZ TSLF AI OFS MDLY CPTA AIW
WallStars show positive broker target price upsides. 78 stocks displayed 10%+ forward yield, $2.50+ prices, and $50M+ market caps as of 8/31/18. Yields above 12.19% narrowed the list to 30.
JE AMID AIC MMLP NAP PER JE AI GMLP MDLY AIW USDP SNMP
2018-08-15 seekingalpha - 1
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
WallStars show positive broker target price-upsides. 66 displayed 10%+ forward yield, at $2+ prices, and $10M+ market caps as of 8/9/18. Yields above 11.88% narrowed this WallStar list to 30.
SNR.WI NGL SNR AIC MCQ MMLP MCV BBDC PER HCLP SNR MCX AI GMLP MDLY CVRR AIW SNMP MCC
2018-08-13 seekingalpha - 1
Following continued requests, this article analyzes fixed-rate agency MBS price movements during the third quarter of 2018 (through 8/10/2018).
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC IVR NYMT FMCCS FMCCT
2018-08-01 seekingalpha - 1
On 7/25/2018, AGNC reported results for the second quarter of 2018. AGNC reported comprehensive income of $148 million and a non-tangible BV as of 6/30/2018 of $19.68 per common share.
NYMTO ORC CHMI NYMTP AI CMO TWO AGNC AIW MO NRZ AIC CYS ARR BXMT 511505 NYMT CAPITALT
I am projecting AGNC will report a minor decrease in quarterly BV for the second quarter of 2018. Most agency peers will also experience a similar type of BV decrease.
NYMTO ORC CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS MTGE MITT MFO DX NLY ARR MFA HTS IVR NYMT
I am projecting AGNC will report a combined modest-notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the second quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC HTS IVR NYMT FMCCS FMCCT
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the second quarter of 2018.
NYMTO MTGE ORC CHMI NYMTP AI TWO AGNC AIW NRZ AIC NLY CYS ARR NYMT
2018-07-03 seekingalpha - 1
The performance of 59 securities, which were selected by SA contributors for their high-yield portfolios in 2014, are identified and analyzed for the period May 2014 to July 2018.
AIY AINV ARI PCI NYMTO HTF KAP OSLE NYMTP KCAP FGB AI CMO TWO SDRL HTFA AGNC AIW SLRA RSO WMC AIC AIB TCRD PSEC NMFC CYS AIF TSLF MCX SCQ XAN PBB SCA MCQ HRZN CHW OXLCO MCV OXLCN STWD.WI MITT SCM HTGZ SLRC BIT MCC TCRX ARCC GBDC CLMT MFO DX NLY TCPC TCRZ HTGX OXLC HTGY ARU OCSL EFC MFA NYMT HTGC STWD
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to AIC / Arlington Asset Investment Corp., 6.75% Senior Bonds due 3/15/2025 on message board site Silicon Investor.
as of ET